Alpha DNA Investment Management LLC Sells 684 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Alpha DNA Investment Management LLC trimmed its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 19.9% during the third quarter, HoldingsChannel.com reports. The firm owned 2,752 shares of the company’s stock after selling 684 shares during the quarter. Alpha DNA Investment Management LLC’s holdings in TransMedics Group were worth $432,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the company. Amalgamated Bank boosted its holdings in shares of TransMedics Group by 6.7% in the 2nd quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after purchasing an additional 70 shares in the last quarter. Harbour Capital Advisors LLC boosted its stake in shares of TransMedics Group by 1.7% during the third quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock valued at $760,000 after purchasing an additional 81 shares during the period. Signaturefd LLC grew its stake in shares of TransMedics Group by 26.6% in the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after purchasing an additional 93 shares during the last quarter. Arizona State Retirement System raised its holdings in shares of TransMedics Group by 2.1% during the second quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock valued at $1,379,000 after acquiring an additional 186 shares in the last quarter. Finally, Venturi Wealth Management LLC lifted its position in shares of TransMedics Group by 33.7% in the 3rd quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock worth $136,000 after purchasing an additional 219 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on TMDX. JPMorgan Chase & Co. dropped their price target on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 29th. TD Cowen cut their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a report on Monday, November 18th. Canaccord Genuity Group decreased their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. Baird R W upgraded TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Finally, Needham & Company LLC reiterated a “hold” rating and issued a $109.00 price objective on shares of TransMedics Group in a report on Friday. Two analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $131.80.

TransMedics Group Trading Down 4.2 %

TMDX stock opened at $76.04 on Monday. The firm has a fifty day moving average price of $119.18 and a 200 day moving average price of $137.84. TransMedics Group, Inc. has a fifty-two week low of $67.77 and a fifty-two week high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The firm has a market cap of $2.55 billion, a PE ratio of 80.89 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). The firm had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. TransMedics Group’s revenue was up 63.7% compared to the same quarter last year. During the same quarter last year, the business posted ($0.12) EPS. Sell-side analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Insider Activity

In other TransMedics Group news, insider Nicholas Corcoran sold 10,000 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total value of $1,760,200.00. Following the completion of the sale, the insider now directly owns 21,105 shares in the company, valued at approximately $3,714,902.10. This represents a 32.15 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the completion of the sale, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $9,457,269.06. The trade was a 12.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 36,958 shares of company stock valued at $5,230,528. 7.00% of the stock is currently owned by company insiders.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.